154 related articles for article (PubMed ID: 19834783)
21. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs.
Jun L; Arnout J; Vanhove P; Dol F; Lormeau JC; Herbert JM; Collen D; Van de Werf F
Coron Artery Dis; 1995 Mar; 6(3):257-63. PubMed ID: 7788040
[TBL] [Abstract][Full Text] [Related]
22. A pilot trial of microplasmin in patients with long-term venous access catheter thrombosis.
Verhamme P; Jerome M; Goossens G; Devis J; Maleux G; Stas M
J Thromb Thrombolysis; 2009 Nov; 28(4):477-81. PubMed ID: 19225865
[TBL] [Abstract][Full Text] [Related]
23. Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis.
Kawasaki T; Katoh M; Kaku S; Gushima H; Takenaka T; Yui Y; Kawai C
Jpn J Pharmacol; 1993 Sep; 63(1):9-16. PubMed ID: 8271535
[TBL] [Abstract][Full Text] [Related]
24. Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
Söhngen W; Mickelson JK; Simpson PJ; Lucchesi BR
Thromb Res; 1988 Jul; 51(1):63-74. PubMed ID: 3137691
[TBL] [Abstract][Full Text] [Related]
25. Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis.
Martin U; Sponer G; König R; Smolarz A; Meyer-Sabellek W; Strein K
Blood Coagul Fibrinolysis; 1992 Apr; 3(2):139-47. PubMed ID: 1606285
[TBL] [Abstract][Full Text] [Related]
26. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
[TBL] [Abstract][Full Text] [Related]
27. Comparison of dose regimens for the administration of recombinant pro-urokinase in a canine thrombosis model.
Burke SE; Lubbers NL; Nelson RA; Henkin J
Thromb Haemost; 1997 May; 77(5):1025-30. PubMed ID: 9184422
[TBL] [Abstract][Full Text] [Related]
28. Thrombolytic effects of recombinant fibrolase or APSAC in a canine model of carotid artery thrombosis.
Markland FS; Friedrichs GS; Pewitt SR; Lucchesi BR
Circulation; 1994 Nov; 90(5):2448-56. PubMed ID: 7955202
[TBL] [Abstract][Full Text] [Related]
29. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
Przyklenk K; Kloner RA
Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
[TBL] [Abstract][Full Text] [Related]
30. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration.
Witt W; Maass B; Baldus B; Hildebrand M; Donner P; Schleuning WD
Circulation; 1994 Jul; 90(1):421-6. PubMed ID: 8026028
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction.
Purvis JA; McNeill AJ; Siddiqui RA; Roberts MJ; McClements BM; McEneaney D; Campbell NP; Khan MM; Webb SW; Wilson CM
J Am Coll Cardiol; 1994 Jan; 23(1):6-10. PubMed ID: 8277097
[TBL] [Abstract][Full Text] [Related]
32. Coronary thrombolysis with recombinant tissue plasminogen activator. Intracoronary vs intravenous administration.
Gu SA; Ducas J; Wolfe K; Patton JN; Prewitt RM
Chest; 1991 Jul; 100(1):201-6. PubMed ID: 1905615
[TBL] [Abstract][Full Text] [Related]
33. Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran.
Uriuda Y; Wang QD; Hatori N; Nordlander R; Sjöquist PO; Mattsson C; Rydén L
J Pharmacol Toxicol Methods; 1998 Mar; 39(2):81-9. PubMed ID: 9694166
[TBL] [Abstract][Full Text] [Related]
34. Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis.
Chen LY; Nichols WW; Saldeen TG; Mehta JL
J Cardiovasc Pharmacol; 1996 Feb; 27(2):283-9. PubMed ID: 8720429
[TBL] [Abstract][Full Text] [Related]
35. Comparison of the recombinant Escherichia coli-produced protease domain of tissue-type plasminogen activator with alteplase, reteplase and streptokinase in a canine model of coronary artery thrombolysis.
Martin U; Kohnert U; Stern A; Popp F; Fischer S
Thromb Haemost; 1996 Dec; 76(6):1096-101. PubMed ID: 8972037
[TBL] [Abstract][Full Text] [Related]
36. Intracoronary vs intravenous bivalirudin bolus in ST-elevation myocardial infarction patients treated with primary angioplasty.
Lupi A; Rognoni A; Cavallino C; Secco GG; Reale D; Cossa G; Rosso R; Bongo AS; Cortese B; Angiolillo DJ; Jaffe AS; Porto I
Eur Heart J Acute Cardiovasc Care; 2016 Sep; 5(5):487-96. PubMed ID: 26163529
[TBL] [Abstract][Full Text] [Related]
37. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
Smalling RW; Bode C; Kalbfleisch J; Sen S; Limbourg P; Forycki F; Habib G; Feldman R; Hohnloser S; Seals A
Circulation; 1995 Jun; 91(11):2725-32. PubMed ID: 7758177
[TBL] [Abstract][Full Text] [Related]
38. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
Yasuda T; Gold HK; Leinbach RC; Yaoita H; Fallon JT; Guerrero L; Napier MA; Bunting S; Collen D
Circulation; 1991 Mar; 83(3):1038-47. PubMed ID: 1900221
[TBL] [Abstract][Full Text] [Related]
39. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
[TBL] [Abstract][Full Text] [Related]
40. Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.
Thiele H; Wöhrle J; Hambrecht R; Rittger H; Birkemeyer R; Lauer B; Neuhaus P; Brosteanu O; Sick P; Wiemer M; Kerber S; Kleinertz K; Eitel I; Desch S; Schuler G
Lancet; 2012 Mar; 379(9819):923-931. PubMed ID: 22357109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
